Search

The Micro, Small, and Medium Enterprise (MSME) sector stands as a pivotal pillar within the Indian economy, contributing to 48% of the nation's production output and providing employment to a staggering 110 million individuals. The pervasive impact of the pandemic has inevitably reverberated across the economic landscape, although its full extent remains shrouded in uncertainty. Particularly, the small-scale enterprises that play a crucial role in India's manufacturing and service domains have borne the brunt of this impact. The year 2020 witnessed an unprecedented deceleration in revenue, with the MSME sector grappling with severe challenges in maintaining operational continuity. In response to this crisis, the government took affirmative action aimed at rejuvenating the beleaguered sector, offering targeted support to MSMEs. This concerted intervention proved to be a significant impetus, infusing hope and vitality into these enterprises. Consequently, a comprehensive evaluation of the barriers encountered, a candid exposition of these hurdles, and the formulation of a robust strategy to surmount the pandemic-induced turmoil have become imperative. In light of this exigency, the researcher undertakes a rigorous analytical investigation into the government's policies crafted to ensure the sustainable growth of MSMEs in India. By distilling insights from diverse sources, a holistic understanding of the challenges faced by MSMEs and the efficacy of governmental interventions is pursued.

Background: Hydaljss08 is a new semisolid fermented hydroalcoholic polyherbal formulation containing crude drug substances. Immunoboost Tab is a novel polyherbal dosage form that is incorporated isolated, and fractionated phytochemical substances. Acute oral toxicity is a primary safety profile of the novel polyherbal formulations. As a part of our study, we estimated acute toxicity safety profile of novel dosage forms by a Swiss albino mice and Wistar rats. Aim: According to the OECD 425 test guideline., the study aims to estimate acute toxicity tests of the “Hydaljss08, and Immunoboost Tab” dosage forms in rats and mice to assess the safety profile. Mice and rats are normally used in safety studies because of their susceptibility to toxic challenges, tumor induction, and carcinogenicity. Material and Methods: 1 % CMC, Hydaljss08, Immunoboost-Tab polyherbal formulations, female rats, and albino mice. Animals were divided into the control groups, and treated groups with test dosage forms. At the end of the study, animals were euthanized by using the CO2 asphyxiation technique and subjected to gross pathological examinations. Results: According to the assessment of the experimental data, the single-dose acute toxicity study of Hydaljss08 and Immunoboost-Tab formulations in mice and rats was fine. No signs of toxicity were observed in the animals treated at (2000 mg/kg.b. wt, Po), and revealed dullness, causing lethargy, and piloerections, which only persisted on the 1st day. At the end of the study, mild congestion in the liver, and lungs was observed in animals, treated with “Hydaljss08 formulation” compared to the vehicle control groups. Conclusions: The estimated LD50 of Hydaljss08, and Immunoboost-Tab polyherbal formulations in rats and mice by oral route was found >2000 mg/kg, b.wt.